Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyze the efficacy and tolerability of cabozantinib-a small molecule inhibitor of MET and VEGFR2-alone or with trastuzumab in patients with breast cancer brain metastases (BCBM).
|
31541381 |
2020 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate concentrations, diagnostic utility and power of VEGF-A, VEGF-C, VEGF-D and VEGFR-2 in comparison to CA15-3 in breast cancer (BC) patients.
|
30387014 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, the inhibitory activity of the novel fused pyrimidine derivatives on VEGFR-2 as well as Tamoxifen was determined using breast cancer cell line MCF-7.
|
30207239 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We tested the combination of anti-PD-1 and different doses of VEGFR2-targeting agents in syngeneic breast cancer mouse models.
|
31848190 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigate whether KDR expression is associated with members in PI3K/Pten signaling on the prognosis of breast cancer patients.
|
31636652 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It was found that both rare homozygotes in the ANLN:rs12535394 and KDR:rs11133360 SNP pair are prognostic of favorable breast cancer survival and underpin the prominent roles of the immune response in cancer state control.
|
31578580 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KDR inferred haplotype is associated with upper limb dysfunction in breast cancer survivors of mixed ancestry.
|
31118800 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, in vitro studies of the VEGFR-2 inhibition in human breast cancer MCF-7 cell line for the promising cytotoxic compounds showed that compounds 7a, 8c, 9b, 9c and 9d were potent inhibitors at low micromolar concentrations (IC<sub>50</sub> = 0.034-0.582 μM) compared to the reference drug, sorafenib (IC<sub>50</sub> = 0.019 μM).
|
30641320 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, negative correlations between circulating EPCs and histological grading as well as a soluble form of VEGFR2 with histological grading of breast cancer according to the Elston-Ellis classification were observed.
|
30818220 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Administration of VGB4 led to the regression of 4T1 murine MCT growth through decreased expression of p-VEGFR1 and p-VEGFR2 and abrogation of ERK1/2 and AKT activation followed by considerable decrease of tumor cell proliferation (Ki67 expression) and angiogenesis (CD31 and CD34 expression), induction of apoptosis (increased p53 expression, TUNEL staining and decreased Bcl2 expression), and suppression of metastasis (increased E-cadherin and decreased N-cadherin, NF-κB and MMP-9 expression).
|
30560942 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmaceutically targeting VEGFR-2 by isomangiferin could be an effective therapeutic strategy for breast cancer.
|
29628979 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Also, elevated expression of PEAK1 and VEGFR2 mRNA are highly correlated in many human cancers including breast cancer.
|
29872538 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The main objectives of the study were to investigate the immunohistochemical expression of vascular endothelial growth factor (VEGF) family ligands (VEGF-A and VEGF-C) and receptors (VEGFR1, VEGFR2 and VEGFR3) in breast cancer and their associations with clinicopathological parameters, cancer subtypes/subgroups and patient outcome.
|
30063723 |
2018 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the impact of vascular endothelial growth factor receptor (VEGFR2) expression and its gene polymorphisms on pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in Russian patients with TN breast cancer.
|
29230610 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Above results proved that, by attenuating the pro-angiogenic communication through VEGFR2, ICJ is a novel angiogenic inhibitor and will be a promising supplement for anti-angiogenic chemotherapy for breast cancer.
|
29403376 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We analyzed tumor vascular density and VEGFR2 protein expression in various subsets of primary human BRCs (186 females; Mean age: 59 years; range 33-88 years), using a tissue microarray.
|
28533703 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In particular, we found that one novel combination, pairing the estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor cabozantinib, dramatically potentiated the drugs' individual antitumor effects in a mouse model of breast cancer.
|
27879272 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer.
|
28894382 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most of the tested compounds showed potent preferential inhibition effects against human VEGFR-2 and remarkable anticancer activities in the human breast cancer cell line MCF-7.
|
28787092 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although VEGFR-2 was normally expressed, VEGF failed to induce proliferation and <i>in vitro</i> tubulogenesis in BC-ECFCs.
|
29221123 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer model was developed with mouse breast cancer cell line 4T1 carrying a reporter system encoding a triple fusion (TF) reporter gene consisting of renilla luciferase (Rluc), red fluorescent protein (RFP) and herpes simplex virus truncated thymidine kinase (HSV-ttk) in transgenic mice, which expressed firefly luciferase (Fluc) under the promoter of vascular endothelial growth factor receptor 2 (Vegfr2-luc).
|
28545358 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This demonstrates that breast cancer can interact with the sensory nervous system to drive neuritogenesis through a VEGF-A/VEGFR2/ARP2/3 mediated pathway.
|
29100335 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade.
|
28680747 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Successful treatment with a combination of anti-VEGFR2 and anti-PD-L1 antibodies induced high endothelial venules (HEVs) in PyMT (polyoma middle T oncoprotein) breast cancer and RT2-PNET (Rip1-Tag2 pancreatic neuroendocrine tumors), but not in glioblastoma (GBM).
|
28404866 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Receptors with intrinsic kinase activity such as EGFR and VEGFR directly or indirectly induce STAT3 activation in various breast cancer types.
|
26559373 |
2016 |